Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Moderate Buy” by Brokerages

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.50.

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Wednesday. Oppenheimer raised their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Canaccord Genuity Group boosted their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th.

Ventyx Biosciences Stock Performance

Shares of VTYX traded down $0.49 on Friday, hitting $8.77. 2,638,343 shares of the stock traded hands, compared to its average volume of 2,134,669. Ventyx Biosciences has a one year low of $0.78 and a one year high of $9.50. The company has a market capitalization of $625.39 million, a PE ratio of -5.22 and a beta of 1.23. The business has a 50 day simple moving average of $4.08 and a 200 day simple moving average of $2.85.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. On average, equities analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC purchased a new position in Ventyx Biosciences in the 1st quarter worth $28,000. Ashton Thomas Private Wealth LLC purchased a new position in Ventyx Biosciences during the second quarter worth approximately $71,000. Nuveen LLC acquired a new stake in Ventyx Biosciences in the first quarter valued at approximately $194,000. Ieq Capital LLC purchased a new stake in shares of Ventyx Biosciences in the first quarter valued at approximately $223,000. Finally, Pallas Capital Advisors LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter worth approximately $38,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.